Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Headlines

Posted By Global Banking and Finance Review

Posted on January 29, 2025

BioVersys launches IPO seeking to raise 80 million Swiss francs

ZURICH (Reuters) - Swiss biopharma company BioVersys said on Wednesday it had launched an initial public offering on the SIX stock exchange priced at 36 Swiss francs ($39.84) per share.

The IPO implied a base offer size of around 75 million francs, rising to about 80 million francs ($88.53 million) if the over-allotment option is fully exercised, the firm said.

Book-building is expected to end on Feb. 5 and the final offer size should be published the next day, with the first day of trading earmarked for Feb. 7, it said.

The company, which focuses on research and development of antibacterial products, said last week about half of the stock would be subscribed by existing shareholders.

Among them, Britain's GSK has committed to investing 3.5 million francs in the IPO, BioVersys said.

($1 = 0.9036 Swiss francs)

(Writing by Dave Graham; Editing by Ludwig Burger)

Recommended for you

  • Soccer-Brighton's Mitoma dumps Chelsea out of FA Cup

  • UK junior health minister sacked by PM Starmer, BBC News reports

  • Tennis-Bencic wins first WTA title as a mother with daughter watching on